BrePco Biopharma Limited is the marketing authorization holder for Neoatricon® (dopamine hydrochloride), a ready-to-use, infant-suitable formulation of dopamine that is approved in the EU for the treatment of hypotension in haemodynamically unstable neonates, infants and children 18 years and below. It is the only formulation of dopamine approved for use in paediatric patients in the EU.